Clinical Trials
22 trialsPhase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Pharma Group Inc.
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Ascentage Pharma Group Inc.
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
Peking University People's Hospital
CAMS-Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Peking University People's Hospital
POLARIS-2
Ascentage Pharma Group Inc.
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
First Affiliated Hospital of Zhejiang University
A Study of Olverembatinib in SDH-deficient GIST.
Ascentage Pharma Group Inc.
ABC
Nanfang Hospital, Southern Medical University
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
Ascentage Pharma Group Inc.
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Ascentage Pharma Group Inc.
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Olverembatinib for FGFR1-rearranged Neoplasms
The First Affiliated Hospital of Soochow University
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
Shenzhen Second People's Hospital
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
Ascentage Pharma Group Inc.
CML
Ascentage Pharma Group Inc.